Visit the home page
Liberpro Advantage Market Milestones
Technology Advantage Market

 

The China Market


Since 2005, MOA and SFDA mandate the manufacturing of drugs, including clinical trial material, in a GMP licensed site

Many small biopharmaceutical companies in China cannot afford to build own plant

Lack of multipurpose GMP certified pilot scale manufacturing facilities

Hence, a niche for a multipurpose facility to serve these clients:

  • Biologics market currently estimated at USD 2.8 billion and to double every 5 years

Our Collaborators in China


  1. National Avian Influenza Reference Laboratory, Animal Influenza Laboratory of the Ministry of Agriculture, Harbin Veterinary Research Institute, CAAS
  2. a) College of Animal Science, b) Laboratory of Veterinary Pharmacology, South China Agricultural University
  3. a) College of Veterinary Medicine, b) State Key Laboratory for Agrobiotechnology, China Agricultural University
  4. College of Animal Science and Technology, Sichuan Agricultural University
  5. Institute of Animal Science, CAAS
  6. Guangxi Veterinary Research Institute
  7. Air Force Hospital, Guangzhou

Our Edge


GreenPak as a biomanufacturing partner:

  • Well-engineered GMP facility at HKIB
  • Extensive experience in process development, fermentation, tissue culture, purification, quality assurance and quality control
  • Experienced in the production of both protein and DNA therapeutics, including DNA vaccines
  • Company culture of respecting IP rights
  • The China connection

 

Back to top